BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 24172289)

  • 21. Ursodeoxycholic acid inhibits hepatic cystogenesis in experimental models of polycystic liver disease.
    Munoz-Garrido P; Marin JJ; Perugorria MJ; Urribarri AD; Erice O; Sáez E; Úriz M; Sarvide S; Portu A; Concepcion AR; Romero MR; Monte MJ; Santos-Laso Á; Hijona E; Jimenez-Agüero R; Marzioni M; Beuers U; Masyuk TV; LaRusso NF; Prieto J; Bujanda L; Drenth JP; Banales JM
    J Hepatol; 2015 Oct; 63(4):952-61. PubMed ID: 26044126
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ursodeoxycholic acid ameliorates hepatic lipid metabolism in LO2 cells by regulating the AKT/mTOR/SREBP-1 signaling pathway.
    Hu J; Hong W; Yao KN; Zhu XH; Chen ZY; Ye L
    World J Gastroenterol; 2019 Mar; 25(12):1492-1501. PubMed ID: 30948912
    [TBL] [Abstract][Full Text] [Related]  

  • 23. New therapeutical indications of ursodeoxycholic acid.
    Copaci I; Micu L; Iliescu L; Voiculescu M
    Rom J Gastroenterol; 2005 Sep; 14(3):259-66. PubMed ID: 16200237
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of ursodeoxycholic acid administration on bile duct proliferation and cholestasis in bile duct ligated rat.
    Frezza EE; Gerunda GE; Plebani M; Galligioni A; Giacomini A; Neri D; Faccioli AM; Tiribelli C
    Dig Dis Sci; 1993 Jul; 38(7):1291-6. PubMed ID: 8325189
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Defective canalicular transport and toxicity of dietary ursodeoxycholic acid in the abcb11-/- mouse: transport and gene expression studies.
    Wang R; Liu L; Sheps JA; Forrest D; Hofmann AF; Hagey LR; Ling V
    Am J Physiol Gastrointest Liver Physiol; 2013 Aug; 305(4):G286-94. PubMed ID: 23764895
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Increased intercellular adhesion molecule-1 serum concentration in cholestasis.
    Polzien F; Ramadori G
    J Hepatol; 1996 Dec; 25(6):877-86. PubMed ID: 9007716
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ursodeoxycholic acid protects against secondary biliary cirrhosis in rats by preventing mitochondrial oxidative stress.
    Serviddio G; Pereda J; Pallardó FV; Carretero J; Borras C; Cutrin J; Vendemiale G; Poli G; Viña J; Sastre J
    Hepatology; 2004 Mar; 39(3):711-20. PubMed ID: 14999689
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of different bile acid-phospholipid conjugates in acute hepatitis.
    Pathil A; Warth A; Chamulitrat W; Stremmel W
    Eur J Clin Invest; 2012 Feb; 42(2):130-8. PubMed ID: 21707612
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ursodeoxycholic acid (UDCA) prevents DCA effects on male mouse liver via up-regulation of CYP [correction of CXP] and preservation of BSEP activities.
    Paolini M; Pozzetti L; Montagnani M; Potenza G; Sabatini L; Antelli A; Cantelli-Forti G; Roda A
    Hepatology; 2002 Aug; 36(2):305-14. PubMed ID: 12143038
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ursodeoxycholate and tauroursodeoxycholate inhibit cholangiocyte growth and secretion of BDL rats through activation of PKC alpha.
    Alpini G; Baiocchi L; Glaser S; Ueno Y; Marzioni M; Francis H; Phinizy JL; Angelico M; Lesage G
    Hepatology; 2002 May; 35(5):1041-52. PubMed ID: 11981754
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long-term effect of treating pregnant rats with ursodeoxycholic acid on the congenital impairment of bile secretion induced in the pups by maternal cholestasis.
    Macias RI; Serrano MA; Monte MJ; Jimenez S; Hernandez B; Marin JJ
    J Pharmacol Exp Ther; 2005 Feb; 312(2):751-8. PubMed ID: 15452192
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mechanism of hepatoprotective action of bile salts in liver disease.
    Stiehl A; Benz C; Sauer P
    Gastroenterol Clin North Am; 1999 Mar; 28(1):195-209, viii. PubMed ID: 10198785
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Short-term TNFα shedding is independent of cytoplasmic phosphorylation or furin cleavage of ADAM17.
    Schwarz J; Broder C; Helmstetter A; Schmidt S; Yan I; Müller M; Schmidt-Arras D; Becker-Pauly C; Koch-Nolte F; Mittrücker HW; Rabe B; Rose-John S; Chalaris A
    Biochim Biophys Acta; 2013 Dec; 1833(12):3355-3367. PubMed ID: 24135057
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ursodeoxycholic acid loaded dual-modified graphene oxide nanocomposite alleviates cholestatic liver injury through inhibiting hepatocyte apoptosis.
    Zhou W; Yang X; Yin Y; Chen S; Yang L; Li T; Liu J; Lu B; Yang Z; Li R; Zhang M
    Colloids Surf B Biointerfaces; 2024 Jun; 238():113904. PubMed ID: 38603845
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ursodeoxycholic acid in cholestasis: linking action mechanisms to therapeutic applications.
    Roma MG; Toledo FD; Boaglio AC; Basiglio CL; Crocenzi FA; Sánchez Pozzi EJ
    Clin Sci (Lond); 2011 Dec; 121(12):523-44. PubMed ID: 21854363
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ursodeoxycholic acid decreases bilirubin-induced osteoblast apoptosis.
    Ruiz-Gaspà S; Dubreuil M; Guañabens N; Combalia A; Peris P; Monegal A; Parés A
    Eur J Clin Invest; 2014 Dec; 44(12):1206-14. PubMed ID: 25331234
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ursodeoxycholic acid in cholestatic liver disease: mechanisms of action and therapeutic use revisited.
    Paumgartner G; Beuers U
    Hepatology; 2002 Sep; 36(3):525-31. PubMed ID: 12198643
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ca2+-dependent cytoprotective effects of ursodeoxycholic and tauroursodeoxycholic acid on the biliary epithelium in a rat model of cholestasis and loss of bile ducts.
    Marzioni M; Francis H; Benedetti A; Ueno Y; Fava G; Venter J; Reichenbach R; Mancino MG; Summers R; Alpini G; Glaser S
    Am J Pathol; 2006 Feb; 168(2):398-409. PubMed ID: 16436655
    [TBL] [Abstract][Full Text] [Related]  

  • 39. TREM-2 plays a protective role in cholestasis by acting as a negative regulator of inflammation.
    Labiano I; Agirre-Lizaso A; Olaizola P; Echebarria A; Huici-Izagirre M; Olaizola I; Esparza-Baquer A; Sharif O; Hijona E; Milkiewicz P; Milkiewicz M; González-Romero F; Aspichueta P; Monte MJ; Marin JJG; Vucur M; Luedde T; Marzioni M; Mann DA; Bujanda L; Rodrigues PM; Banales JM; Perugorria MJ
    J Hepatol; 2022 Oct; 77(4):991-1004. PubMed ID: 35750136
    [TBL] [Abstract][Full Text] [Related]  

  • 40. 24-nor-ursodeoxycholic acid ameliorates inflammatory response and liver fibrosis in a murine model of hepatic schistosomiasis.
    Sombetzki M; Fuchs CD; Fickert P; Österreicher CH; Mueller M; Claudel T; Loebermann M; Engelmann R; Langner C; Sahin E; Schwinge D; Guenther ND; Schramm C; Mueller-Hilke B; Reisinger EC; Trauner M
    J Hepatol; 2015 Apr; 62(4):871-8. PubMed ID: 25463533
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.